FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Landsittel Michael  (Last) (First) (Middle)  C/O BLUEPRINT MEDICINES CORPORATION  45 SIDNEY STREET						Issuer Name and Ticker or Trading Symbol     Blueprint Medicines Corp [ BPMC ]  3. Date of Earliest Transaction (Month/Day/Year) 03/01/2020								Relationship of Reporting Person(s) to Issuer leck all applicable)  Director 10% Owner  X Officer (give title below)  Chief Financial Officer				ner
(Street)  CAMBRIDGE MA 02139  (City) (State) (Zip)				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								i. Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	`	-		n-Deriv	vativ	e Se	curities	S Acc	uired. F	Disr	nosed o	f. or Be	neficia	ly Owned	<u> </u>			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					saction	n ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			5. Amou Securitie Benefici Owned F	nt of es ally following	Form	Direct Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) o	r Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(11150.4)	
Common Stock 03/01/					1/202	2020			A		12,50	12,500 A		17,750(1)			D	
		-	Table II -						ired, Di					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transaction Code (Insti				6. Date Exercisable Expiration Date (Month/Day/Year)			and 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$54.13	03/01/2020			A		25,000		(2)	0	3/01/2030	Common Stock	25,000	\$0	25,000	)	D	

## **Explanation of Responses:**

- 1. The reported transaction involved the Reporting Person's receipt of a grant of 12,500 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 12,500 newly awarded restricted stock units, and 5,250 previously reported restricted stock units, 1,313 of which vested on March 1, 2020.
- 2. This option vests with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter.

/s/ Christopher Frankenfield, Attorney-in-Fact

03/03/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.